{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T18:22:30Z","timestamp":1723054950586},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:p>Objective. There are generic fixed-dose combinations (FDCs) of ritonavir-boosted darunavir (DRV\/r) available in Argentina. Experiences with these FDCs in dual therapy remain limited in clinical practice. We aimed to describe clinical and virologic outcomes in patients exposed to FDC DRV\/r + raltegravir (RAL) 400 mg every 12 h in a real-life setting. Patients and methods. Retrospective analysis of electronic medical records of HIV-infected patients under FDC DRV\/r + RAL in an HIV clinic in Argentina (2014-2018). Individuals were classified as \u201cswitch group\u201d (SG, undetectable viral load [VL] with any toxicity\/comorbidity) and \u201cvirologic group\u00b7 (VG, detectable viremia and infection by multidrug-resistant HIV). Results. Of 7,380 patients on ART, 116 (1.5%) received FDC DRV\/r + RAL, being 58% in SG. Sixty percent received DRV\/r 800\/100 mg dose (rest, 600\/100 mg). The median (IQR) age and CD4+ T-cell count were: 52 (42-58) years, and 373 cell\/\u00b5L (202-642). Ninety-eight percent were ART-experienced with a median of 3 (IQR 2-5) prior treatments. Main reasons for switch (SG) were renal (57%), cardiovascular (54%) and bone (14%) comorbidities. Median exposure to DRV\/r + RAL was 18 months. Among patients in SG, 98% and 96% had undetectable VL at 6 and 12 months; in the VG, 89% and 87% had undetectable VL at 6 and 12 months. No patient required suspension due to toxicity\/ intolerance. Conclusion. In this cohort of mostly experienced HIV-infected patients, FDC DRV\/r + RAL was effective and safe. Such therapy may be considered an option for patients with comorbid conditions and\/or with multidrug-resistant HIV.<\/jats:p>","DOI":"10.37201\/req\/090.2020","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T09:21:48Z","timestamp":1606987308000},"page":"56-60","source":"Crossref","is-referenced-by-count":0,"title":["Dual therapy with raltegravir plus a fixed dose combination of darunavir\/ritonavir in people living with HIV in Argentina"],"prefix":"10.37201","volume":"34","author":[{"given":"Fernanda","family":"Rombini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego M.","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamile","family":"Ballivian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Huberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anal\u00eda","family":"Urue\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Cassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Helios Salud, Buenos Aires, Argentina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"23328","published-online":{"date-parts":[[2020,12,3]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":[],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T06:21:32Z","timestamp":1612851692000},"score":1,"resource":{"primary":{"URL":"https:\/\/seq.es\/abstract\/rev-esp-quimioter-2020-december-3-2\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/090.2020","relation":{},"ISSN":["0214-3429","1988-9518"],"issn-type":[{"type":"print","value":"0214-3429"},{"type":"electronic","value":"1988-9518"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}